- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Robbins LLP Investigates Atara Biotherapeutics Stock Losses
Law firm encourages investors with significant losses to contact them about potential rights against ATRA.
Apr. 1, 2026 at 12:51am
Got story updates? Submit your updates here. ›
Robbins LLP has filed a class action lawsuit on behalf of investors who purchased or acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. The complaint alleges that Atara misled investors about the prospects of its lead drug candidate, tabelecleucel, including manufacturing issues and problems with the ALLELE study design that made FDA approval unlikely.
Why it matters
Atara Biotherapeutics is a biotech company focused on developing therapies for solid tumors, blood cancers, and autoimmune diseases. Its lead product candidate, tabelecleucel, was seen as a key driver of the company's future growth. The allegations that Atara misled investors about the drug's regulatory prospects could have significant financial implications for the company and its shareholders.
The details
According to the complaint, Atara failed to disclose that manufacturing issues and problems with the ALLELE study design made it unlikely the FDA would approve tabelecleucel. The company allegedly overstated the drug's regulatory prospects, subjecting Atara to heightened regulatory scrutiny and jeopardizing its ongoing clinical trials. On January 12, 2026, Atara announced the FDA had issued another Complete Response Letter regarding the tabelecleucel BLA, stating the ALLELE trial was no longer considered adequate to provide evidence of effectiveness. This news caused Atara's stock price to plummet nearly 57%.
- The class period is from May 20, 2024 to January 9, 2026.
- On January 12, 2026, Atara announced the FDA had issued another Complete Response Letter regarding the tabelecleucel BLA.
The players
Atara Biotherapeutics, Inc.
A biotech company developing therapies for solid tumors, blood cancers, and autoimmune diseases, with a focus on its lead drug candidate tabelecleucel.
Robbins LLP
A law firm that has filed a class action lawsuit on behalf of investors who purchased Atara Biotherapeutics stock during the class period.
What’s next
Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by May 22, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
The takeaway
This case highlights the risks investors face when biotech companies provide overly optimistic information about their drug development pipelines. Shareholders will be closely watching to see if Atara is held accountable for allegedly misleading investors about the regulatory prospects of its key drug candidate.
